Literature DB >> 23893235

Top 10 developments in lupus nephritis.

Teresa K Chen1, Derek M Fine.   

Abstract

Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23893235     DOI： 10.1007/s11926-013-0358-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  48 in total

1.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Successful mycophenolate mofetil treatment of glomerular disease.

Authors:  W A Briggs; M J Choi; P J Scheel
Journal:  Am J Kidney Dis       Date:  1998-02       Impact factor: 8.860

3.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

4.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

5.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

6.  Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.

Authors:  Michelle Petri; William Stohl; Winn Chatham; W Joseph McCune; Marc Chevrier; Jeff Ryel; Virginia Recta; John Zhong; William Freimuth
Journal:  Arthritis Rheum       Date:  2008-08

7.  Mycophenolate mofetil therapy in lupus nephritis: clinical observations.

Authors:  M A Dooley; F G Cosio; P H Nachman; M E Falkenhain; S L Hogan; R J Falk; L A Hebert
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

8.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

Review 9.  The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

Authors:  Michael P Cancro; David P D'Cruz; Munther A Khamashta
Journal:  J Clin Invest       Date:  2009-05-01       Impact factor: 14.808

10.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103
View more
  1 in total

1.  Renal transplantation in systemic lupus erythematosus: outcome and prognostic factors in 50 cases from a single centre.

Authors:  Ernesto Cairoli; Carolina Sanchez-Marcos; Gerard Espinosa; Constanza Glucksmann; Guadalupe Ercilla; Federico Oppenheimer; Ricard Cervera
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.